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The serotonin transporter (5-HTT) gene contains a variable number tandem repeat (VNTR) domain within intron 2 that is often associ-
ated with a number of neurological conditions, including affective disorders. The implications of this polymorphism are not yet under-
stood, however, we have previously demonstrated that the 5-HTT VNTR is a transcriptional regulatory domain, and the allelic variation
supports differential reporter gene expression in vivo and in vitro. The aim of this study was to identify transcription factors responsible
for the regulation of this VNTR. Using a yeast one-hybrid screen, we found the transcription factor Y box binding protein 1 (YB-l)
interacts with the 5-HTT VNTR. Consistent with this, we demonstrate in a reporter gene assay that the polymorphic VNTR domains
differentially respond to exogenous YB-l and that YB-l wiII bind to the VNTR in vitro in a sequence-specific manner. Interestingly, the
transcription factor CCTC-binding factor (CTCF), previously shown to interact with YB-l, interferes with the ability of the VNTR to
support YB-l-directed reporter gene expression. In addition, CTCF blocks the binding ofYB-l to its DNA recognition sequences in vitro,
thus providing a possible mechanism of regulation ofYB-l activation ofthe VNTR by CTCF. Therefore, we have identified YB-l and CTCF
as transcription factors responsible, at least in part, for modulation ofVNTR function as a transcriptional regulatory domain. Our data
suggest a novel mechanism that explains, in part, the ability of the distinct VNTR copy numbers to support differential reporter gene
expression based on YB-l binding sites.
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Introduction
Mutation or inappropriate expression of the serotonin trans-
porter (5-HTT) gene has been postulated as a possible predispos-
ing factor in many CNS-related disorders, including numerous
studies of affective disorders. The human gene encompasses 15
exons spanning -31 kb on chromosome 17qll (Lesch et aI.,
1994). No differences in amino acid sequence have been found
between healthy controls and affective disorder patients, how-
ever, associations between two polymorphisms found in noncod-
ing regions of the 5-HTT gene and susceptibility to affective dis-
order have been reported (Collier et aI., 1996; Battersby et aI.,
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1997; Heils et aI., 1997; Mellerup et aI., 2001; Bellivier et aI., 2002).
This association, nevertheless, remains controversial because it
has not always been reproducible (Hoehe et aI., 1998). We have
been addressing the function of one of these polymorphisms
within intron 2 of the 5-HTT gene, which is also potentially a
predisposing factor for a number of other neurological disorders
such as attention deficit hyperactivity disorder and autism (Kent
et aI., 2002; Conroy et aI., 2004). Three allelic variants of this
variable number tandem repeat (VNTR) (Stin2.9, Stin2.10, and
Stin2.12) containing, respectively, 9,10, or 12 copies ofa repeated
16 or 17 bp element have been identified (Battersby et aI., 1996;
Ogilvie et aI., 1996; Ogilvie and Harmar, 1997) (see Fig. 1). We
have demonstrated that the different repeat number within the
VNTR supports differential expression in vitro (Fiskerstrand et
aI., 1999; Lovejoy et al., 2003) and both differential and tissue-
specific expression in vivo (MacKenzie and Quinn, 1999) in a
transgenic model. It has also been demonstrated that the VNTR
genotype correlates with the number of platelet 5-HTT trans-
porters in patients with affective disorders (Mellerup et aI., 2001).
Characterization of the transcription factors that bind to the
VNTR and determination of their ability to support differential
expression is one approach to identify the signal transduction
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pathways contributing to neurological disorders in which these
5-HTTintron 2 polymorphisms are implicated.
Here, we report the first identification of transcription factors
that mediate differential expression supported by the VNTRs. We
demonstrate that the 5-HTT intron 2 VNTR is bound and regu-
lated by the Y box binding protein 1 (YB-1) transcription factor,
a member of the large family ofY box binding proteins (Wolffe et
aI., 1992; Wolffe, 1994; Swamynathan et aI., 1998; Kohno et aI.,
2003). YB-1 regulation of the VNTR is modulated by the tran-
scription factor CCTC-binding factor (CTCF), which we have
identified previously as a binding partner ofYB-1 (Chernukhin et
aI., 2000). CTCF, in addition to transcriptional silencing or acti-
vating in a context-dependent manner, organizes epigenetically
controlled chromatin insulators that regulate imprinted genes in
soma (Klenova et aI., 1993; Filippova et aI., 1996; Ohlsson et aI.,
2001; Klenova et aI., 2002). CTCF has been implicated previously
in the deregulation ofother neuronal-specific genes (Vostrov and
Quitschke, 1997; Burton et al., 2002; Vostrov et aI., 2002). Our
data and model for regulation of the VNTR provides insights into
the molecular mechanisms associated with development of neu-
rological disorders in which the 5-HTT gene is implicated.
Materials and Methods
Yeast one-hybrid screen. The yeast one-hybrid assay was conducted using
the MATCHMAKER One-Hybrid System, and all experimental proce-
dures were performed according to the manufacturer's instructions
(Clontech, Cambridge, UK). Briefly, the Stin2.10 VNTR DNA (Mac-
Kenzie and Quinn, 1999) was used as bait to identify interacting proteins
expressed from a human fetal brain MATCHMAKER cDNA library
(Clontech). Diploid yeast clones were obtained that contained individual
plasmids from the cDNA library. Plasmid DNA was isolated according to
the manufacturer's instructions, using a yeast DNA isolation system
(Stratagene, La Jolla, CAl. The plasmids were then subjected to DNA
sequence analysis to determine which cDNAs they encoded. Verification
of binding was as per the manufacturer's instructions.
Plasm ids. The full-length cDNA for the YB-l gene was subcloned from
the pSFFV-YB-I plasmid, obtained as a kind gift from Dr. J. Ting (Uni-
versity ofNorth Carolina, Chapel Hill, NC), into the mammalian expres-
sion vector pcDNA3 (Invitrogen, San Diego, CAl. The expression plas-
mid for the chicken CTCF gene, pCTCF, has been described previously
(Klenova et a!', 2001). The reporter constructs Stin2.9, Stin2.10, and
Stin2.12 use the luciferase reporter construct pGL3P and were reported
previously (Fiskerstrand et a!', 1999).
Cell cultures, transient transfeetions, and luciferase assay. COS7 and
HEK (human embryonic kidney) 293T cells were maintained in DMEM
supplemented with 10% FCS and 50 JLglml gentamycin. Cells were trans-
fected using a standard calcium precipitation method (Sambrook and
Russell, 200 I). A total of 10 5 cells was plated in a 12-well plate format and
transfected (0.5-3 JLg plasmid per well) after a 24 hr growth with the
reporter gene and expression vectors. To normalize for cell number and
transfection efficiency, 0.25 JLg of l3-galactosidase marker gene vector
(pCI-! 110) was added per well. Cells were washed 24 hr after transfection,
harvested at 48 hr, and assayed using the Luciferase Assay System (Pro-
mega, Madison, WI) and Labsystems Luminoskan (Life Sciences, Hi-
aleah, FL), according to the manufacturers' instructions.
Transfections were performed in triplicate in at least three indepen-
dent experiments, and the mean normalized luciferase values were cal-
culated together with the SEM.
Expression and purificatio11 ofthe recombinant YB-l and CTCFprotei11S.
Five YB-l variants were constructed, in a modified pGEX-2Texpression
vector using the Neal and EcoRI sites. Briefly, primers containing the
Neal and EeoR! restriction sites (sequences available on request) were
used for PCR amplification. The fragments were designed as described
previously (Jurchott et a!', 2003): pGEX-YB-I(I) contains aa 21-317,
pGEX-YB-l(2) contains aa 21-225, pGEX-YB-I(3) contains aa 21-147,
pGEX-YB-l(4) contains aa 146-317, and pGEX-YB-I(5) contains aa
146-225. A schematic representation of each mutant is shown in Figure
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4A. The PCR fragments were subcloned into the intermediate vector
pGEM-T (Promega), excised, ligated into the Ncol/EcoRI sites of the
vector pGEX-2T (Amersham Pharmacia Biotech), and the recombinant
constructs were verified by sequencing.
Transformation of Escherichia coli and induction of the glutathione
S-transferase (GST) fusion proteins were performed as reported by
Smith and Johnson (1988) and Klenova et al. (1997). The expressed
truncated YB-l proteins were prepared by sonication in binding buffer
(50 mM Tris-CI, pH 8.0, I mM EDTA, 120 mM NaC!, 0.5% NP-40, 10%
glycerol, and I mM PMSF). Purification of the CTCF protein expressed in
the baculovirus system was performed according to Chernukhin et a!'
(2000).
EMSA and Western blot analysis. The conditions for EMSA and West-
ern blot analysis were as reported previously (Chernukhin et a!', 2000).
The double-stranded DNA fragments for EMSA were obtained by PCR as
according to Fiskerstand et a!' (1999). Primers for amplification were as
follows: VNTR forward, 5'-ATGGCGCGCCGGTACCTCACAGGCT-
GCGAGTAGA-3'; VNTR reverse,S' -AACGGCGCGCCTCGAGTGGC-
CTCTCTCAAGAGGA-3'; T7 primer, 5'-TAATACGACTCACTAT-
AGGG-3'; UI9 primer, 5'-GTITICCCAGTCACGACGT-3'.
We also used the annealed primers corresponding to the YB-I binding
sites designed as follows: (I) VNTR 3/4 (HindIIIIXbaI ends, SmaI is in
italics): AGCTTGACCCGGGGTGGGCTGTGAT, ACTGGGCCCCAC-
CCGACACTAGATC; (2) VNTR 6/7 (HindIlI/Xba! ends, Sma! is under-
lined): AGCTTCCTGGGATGGGCTGTGACCCGGGT, AGGACCCT-
ACCCGACACTGGGCCCAGATC; (3) YB-I from mdr-I (Jurchott et a!.,
2003) (HindIlI/XbaI ends, ApaI is underlined): AGCTIGAGGCTGAT-
TGGCTGGGCCCT, ACTCCGACTAACCGACCCGGGAGATC; (4)
YB-I from mdr-I mut (HindIIlIXbal ends, Apal is underlined, mutated
nucleotides are shown in bold italic): AGCTTGAGGCTCAGTACrr-
GGGCCCT, ACTCCGAGTCATGAACCCGGGAGATe.
Production of in vitro tra11Slated deletio11 mutants ofZn finger domains.
To generate the [ 35S]Met-labeled full-length CTCF-Zn finger (ZF) do-
main, we used plasmid p4a-ZF (I-II) (Filippova et a!', 1996). In vitro
translation was performed according to the protocol suggested by the
manufacturer (Prom ega).
In vitro interaction assay using the immobilized CTCF-ZF domain. Son-
icated bacterial lysates containing YB-I derivatives were used in the in-
teraction experiments. Bacterial lysate was passed through the matrix
with the immobilized CTCF-ZF domain, prepared as described previ-
ously (Chernukhin et a!., 2000). After washing three times in the high-salt
binding buffer (50 mM Tris-Cl, pH 8.0, I mM EDTA, 500 mM NaCI, 0.5%
NP-40, 10% glycerol, and I mM PMSF), the samples were subjected to
SDS-PAGE and immunoblotted with anti-GST goat antibody ( Amer-
sham Biosciences, Piscataway, NJ).
In vitro interaction assay using the immobilized YB-l mutants. The
bacteriallysates of truncated YB-l deletion mutants were produced and
coupled with glutathione-Sepharose, as described previously (Smith and
Johnson, 1988). The interaction assay was performed as follows: 2 JLI of in
vitro translated ZF II was mixed with 50 JLI of each individual YB-!
mutant bound to glutathione-Sepharose beads in 500 JLI of binding
buffer (50 mM Tris-Cl, pI-! 7.4, ISO 111M NaCl, 5 mM EDTA, 0.5% NP-40,
and I mM PMSF) for 4 hr at 4°e. The complexes were washed three times
in washing buffer (50 mM Tris-CI, pH 7.4,500 mM NaCI, 5 mM EDTA,
0.5% NP-40, and 1 mM PMSF), and the proteins bound to beads were
eluted with protein sample buffer and separated by SDS-PAGE. The gel
was then fixed and vacuum dried for 2 hr at 75°C and exposed to x-ray
film overnight at -70°e.
Results
Yeast one-hybrid screening
Initial screening of the pretransformed human fetal brain cDNA
library generated candidate diploid clones of potential interest.
Clones were picked at random, and levels of marker gene expres-
sion within these clones were analyzed further, and several clones
were identified as candidates for plasmid isolation. The nature of
cDNA inserts present was then determined by DNA sequence
analysis. Several clones contained a fragment of cDNA for the
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(Fiskerstrand et aI., 1999; MacKenzie and Quinn, 1999; Lovejoy
et a1., 2003). To further investigate the ability ofYB-1 to regulate
the VNTR domains, we used luciferase reporter gene constructs
containing VNTR domains inserted upstream of the SV40 pro-
moter termed pStin2.9Luc, pStin2.lOLuc, and pStin2.12 Luc. A
series of standard cotransfection assays were performed with
these reporter constructs and with a vector expressing full-length
YB-1 (pYB-l) in COS7 cells. We found that YB-1 can differen·
tially regulate the polymorphic VNTR domains in these cells. As
shown in Figure 2A, the most significant effect was observed
from the Stin2.9 VNTR variant, which was strongly and progres-
sively activated by increasing amounts of pYB-I. In COS7 cells,
the reporter gene pStin2.10 Luc did not respond to exogenous
YB-1, and the plasmid pStin2.12 Luc was slightly repressed with
increasing amounts of pYB-I. YB-1 can also exert a cell-specific
affect, because we demonstrated that Stin2.10 is activated in ad-
dition to Stin2.9 in HEK 293T cells (Fig. 2C). The latter suggests
evidence for cell-specific factors that can directly modulate the
function ofYB-l or that differentially affect VNTR function.
Figure 2. YB-1differentially activates the distinct VNTR domains in a cell-specific manner,
and CTCF abrogates the activating function ofYB·1. Cells weretransfected, and luciferaseassays
were performed. Transfections were performed in triplicate in at least three independent ex-
periments, and the mean normalized luciferase values were calculated together with the 5EM,
represented by error bars.A, Titration of pYB·1plasmid with 1J.Lg ofluciferase reporter in COS7
cells. B, Cotransfection of CTCF, YB-1, and the VNTR-Iuciferase reporters into C057 cells. C
Cotransfection of CTCF, VB·1, and the VNTR-Iuciferase reporters into HEK 293T cells.
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Polenl!al YB·I binding slles wllhln SUn2.12 VNTR used In EMSA
A
YB-I can specifically and differentially activate the
distinct VNTR domains in a tissue-specific manner in a
cotransfection assay
We have previously demonstrated the ability of the VNTR do-
mains to support reporter gene expression in vivo and in vitro
Figure 1. Schematic representation of the structure and sequence of the 5tin 2VNTR. A, The
5tin 2.12 VNTR sequence showing individual repeats (RP1 through RP1 2) and unique elements
based on primary sequence (a, b, c, d, e, f, g). Potential VB·1binding sites are underlined, and
two sequences were selected from the repeats 3/4 and 6/7 and analyzed further in EM5A. B,
VNTR polymorphisms within the serotonin transporter intron 2. Two distinct polymorphisms,
5t2.10 and 5t2.9, vary in the location and number of deletions of the repeats as indicated by
5t2.10 (filled boxes) or 5t2.9 (hatched boxes). Transcription start site is indicated by an arrow.
human YB-1 (GenBank accession number )03827) (Didier et a1.,
1988). The eDNA was complete, except for a short N·terminal
truncation corresponding to the first 18 amino acids of the full-
length wild-type protein.
Inspection of the VNTR sequence identified several potential
binding sites for YB-1 spanning the region between the individual
repeat elements (Fig. 1A, red) that would be in agreement with
the consensus of the recognition motif for the family of Y box
binding proteins (Fig. 1A) (Didier et aI., 1988; Wolffe et aI., 1992;
Wolffe, 1994). The identification of this protein was significant
because its DNA-binding consensus sequences, depending on the
alignments of a G·rich stretch within or flanking the potential
YB-1 site, are located in the area that predominantly both dem-
onstrates primary sequence variation between the individual re-
peats in the VNTR and the variation that accounts for the differ-
ence in size of the repeats, either 16 or 17 nucleotides (Fig. 1A).
This suggested strongly to us that YB-1 not only might affect
expression supported by the VNTR but also the differential ex-
pression observed. Thus, in our initial studies reported here, it
was decided to determine whether YB-1 played any role in tran-
scription supported by the VNTR in intron 2.
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GST component of the fusion protein (Fig. 3B, lane 6), Complex
1 was detected only when 0.5 /Lg ofYB-I was used in the EMSA
reaction; however, complexes 2 and 3 could be seen with increas-
ing amounts ofYB-I protein (Fig, 3A, lanes 1-3,6-8, and 11-
13), Complexes 1,2, and 3 may reflect the occupancy of different
sites within the VNTR domain by YB-I as increasing amounts of
this protein are added to the reaction or result from multimer-
ization ofYB-1 (Izumi et al., 2001). All three bands were com-
peted when unlabeled mdr-I sequences containing the well char-
acterized YB-1 binding site were included in the reaction (Fig. 3A,
lanes 4 and 5, 9 and 10, and 14 and 15). This competition was not
observed using the mutated mdr-1 oligonucleotide (Fig. 3B, lane
7), thus confirming multiple sequence-specific YB-1 binding
sites are present in all three VNTR domains.
YB-I binds to Stin2 VNTR in vitro
To confirm that the VNTRdomain contain binding sites forYB-1
protein, we performed EMSA analysis using end-labeled prod-
ucts ofStin2.9, Stin2.1O, and Stin2, 12, As shown in Figure 3A, all
three fragments form complexes with the bacterially produced,
purified GST- YB-I fusion protein. The specificities ofthese com-
plexes were confirmed because bands were not detected with the
Figure 3. Analysis of the YB-l interactions with VNTR domains in EMSA. A, Bacterially ex-
pressed YB-1 can form specific complexes with the 32P-labeled Stin 2.9, Stin 2.1 0, and Stin 2.12
DNA. Each incubation mixture contained the same amount of nonspecific competitor
poly(deoxyinosinic-deoxycytidylic) acid (dldC) (0.1 /Lg); 1/Lg ofG5T-YB-l fusion was added to
samples in lanes 1, 6, and 11; 2/Lg of GST-YB-l was added to samples in lanes 2,7, and 12; 4
/Lg ofGST-YB-l was added to samples in lanes 3-5, 8-10, and 13-15. The specific competitor
mdr-l oligonucleotide was added as follows: lanes 4and 9, and 14- to 50-fold molar excess;
lanes 5and 10, and 15- to lOa-fold molar excess. The positions of DNA-protein complexes are
indicated (labeled 1, 2, and 3). e, Competition EM5A analysis. The labeled Stin 2.12 DNA frag-
ment was incubated with the same amount of nonspecific competitor dldC (0.1 /Lg) and 2/Lg
of GST-YB-l protein in all reactions (except 6, in which a2/Lg of GST component ofthe fusion
protein was added). Competitors tested in this experiment were as follows: lane 2, lOa-fold
molar excess of rp 6/7 oligonucleotide; lane 3, lOa-fold molar excess of rp 3/4 oligonucleotide;
lane 4,0.5 /Lg ofbaculoCTCF; lane 5,1 /Lg ofbaculoCTCF; lane 6, 2/Lg of GST; lane 7, lOa-fold
excess of the mdr-l mutated oligonucleotide that is unable to bind YB-l. C. EMSAanalysis ofthe
competition with rp 3/4 -G5T-YB-l complexes. Incubation mixtures contained labeled rp 3/4
oligonucleotide, nonspecific competitor dldC (0.1 /Lg), and 2 /Lg of GST- YB-l. DNA-protein
complexes were preformed during a 30 min incubation on ice, then the competitors were
added, and incubation continued for an additional 20 min. Competitors were added as follows:
lane 1, no competitor; lanes 2-5, 10-, 25-, 50-, and lOa-fold molar excess of oligonucleotide
mdr-1, respectively; lanes 6-9, 0.25, 0.5, 1, and 2 /Lg of baculoCTCF, respectively. D, EM5A
analysis of the competition with rp 617-G5T-YB-l complexes. The incubation mixtures con-
tained labeled rp 6/7 oligonucleotide, nonspecific competitor dldC (0.1 /Lg), and 2/Lg of G5T-
YB-l.ln (and D, DNA-protein complexes were preformed during a30 min incubation on ice,
then the competitors were added, and incubation continued for an additional 20 min. Compet-
itors were added as follows: lane 1, no competitor; lanes 2-8,10-,25-,50-,100-,150-,200-,
and 250-fold molar excess of oligonucleotide mdr-l, respectively; lanes 9-12, 0.25, 0.5,1, and
2/Lg of baculoCTCF, respectively.
Characterization of two classes of potential YB-I binding
sites, dependent on primary DNA sequence, within the
VNTR domains
The majority ofthe YB-1 sites identified within the longest VNTR
domain, Stin2.l2, have the core sequence GGTGGGCT, but one
site has the YB-1 binding site core sequence, GATGGGCT (Fig.
lA). For additional analysis, we designed oligonucleotides con-
taining these two variants of the YB-l binding sequence (YB-l
site 1, termed rp 3/4, and YB-l site 2, termed rp 6/7). When these
were used in EMSA experiments competing with the longest
VNTR domain, Stin2.12, both oligonucleotides were able to dis-
sociate YB-l-VNTR complexes (Fig. 3B), providing evidence that
these sites are involved in the formation of these complexes.
Additional experiments shown in Figure 3C demonstrate that
YB-l produces four complexes with rp 3/4, however, only two
complexes, d and c, are efficiently removed by competition with
the double-stranded mdr-1 oligonucleotide (lanes 1-5). The oli-
gonucleotide rp 617, corresponding to the second type of poten-
tial YB-1 site, generated a different binding pattern with YB-1
protein (Fig. 3D, lane 1). Two complexes are clearly seen with a
very faint slower migrating complex (c') occasionally observed.
All binding to this site can be removed by competition from the
mdr-1 oligonucleotide. However, a greater concentration of the
oligonucleotide is required to dissociate complexes a' and b' than
the specific complexes observed on rp 3/4 (Fig. 3D, lanes 2- 8).
BindingofYB-l to the VNTR is inhibited by CTCF
We have previously demonstrated that YB-1 interacts with the
transcription factor CTCF (Chernukhin et al., 2000). Therefore,
we investigated whether CTCF would modulate YB-1 binding to
the Stin12 VNTR-YB-1, rp 3/4-YB-1, and rp 617-YB-1 com-
plexes. As shown in Figures 3B (lanes 4 and 5), 3C (lanes 6-9),
and 3D (lanes 9-12), CTCF produced in the baculoviral system
could dissociate complexes ofYB-l from the full-length VNTR
domain (Stin2.12) and the individual VNTR elements. This in-
hibition ofYB-1 binding could be via the CTCF protein binding
more avidly to the DNA, and stereotaxically inhibiting YB-l in-
teractions or CTCF could bind toYB-1 in a manner that blocked
the YB-1 DNA binding domain recognizing the consensus se-
quence. We postulated the latter because (l) we have previously
observed YB-1-CTCF interactions via the CTCF ZF domain
(Chernukhin et al., 2000) and (2) binding of CTCF rather than
YB-l to the VNTR sequence would have led to the appearance of
complexes that would be observed in our EMSA; clearly these are
not seen under our experimental conditions in Figure 3.
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CTCF abrogates YB-I-induced reporter gene supported by
VNTRs Stin2.9 and Stin2.10
To investigate whether CTCF interferes with the activating func-
tion of YB-l on the VNTR, we performed transient cotransfec-
tion assays using vectors expressing the full-length CTCF
(pCTCF) and YB-l (pYB-l) and the reporter gene plasmids con-
taining the VNTR domains. As shown in Figure 2, Band C, CTCF
alone has no effect on the expression from all three reporter
plasmids, However, when pCTCF was cotransfected together
with pYB-l and the reporter gene plasmid containing Stin2.9,
CTCF strongly inhibited expression of the reporter in both cell
lines tested (COS7 and HEK 293T). CTCF also interfered with the
activation of the Stin2.10 reporter construct by YB-l in HEK
293T (Stin2,10 was not activated by YB-l in COS7 cells).
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to interact with the CTCF-ZF was tested in the reverse experi-
ment, in which the truncated variants ofYB-l were immobilized
on the matrix and the in vitro translated 35S-labeled ZF domain of
CTCF was in solution. As shown in Figure 4D, the CTCF-ZF was
retained by GST-YB-l(1) and GST-YB-l(3), a weaker signal can
be seen in GST-YB-l(2), but no CTCF-ZF was detected with
immobilized GST-YB-l(4) and GST-YB-l(5). There was no sig-
nal from the labeled ZF domain in either of the negative controls
(GST only and BSA-Sepharose), confirming that the YB-l inter-
action with CTCF-ZF uses sequences in the N-terminal CSD
domains.
Discussion
The aim of this study was to identify transcription factors respon-
sible for the regulation of the 5-HTT intron 2 VNTR function.
We have demonstrated that two proteins, YB-l and CTCF, play
Figure 4. YB-1interacts with ClCF in the region that contains the YB-1CSO, A, Schematic
representation of the truncated versions of GST- YB-1, Gray box, N-terminal domain; black box,
CSO; open box, C-terminal domain, The ovals represent the GST portion of each truncated
variant. B, Western blot of the truncated YB-1variants expressed in E. coli, The fusion proteins
were prepared as described in Materials and Methods, resolved in 10% 50S-PAGE and probed
with the anti-GST·1antibody, The arrows indicate the positions of degraded G5T-YB-1(4) pro-
tein, C, In vitro interaction assay between the CTCF-ZF domain coupled with the matrix and a
panel of truncated YB-' variants expressed in E. coli. For the interaction assay, the CTCF-Zn
domain coupled with Sepharose was incubated individually with the GST-YB-1variants, then
washed with 0,25 M radioimmunoprecipitation assay (RIPAj buffer. Proteins retained on the
matrices were analyzed by 50S-PAGE, followed by immunoblotting with the anti-GST-1anti-
bodies. The GST protein was used as acontrol. Asterisks at the left side of the lanes show the
positions of cognate proteins seen in B. 0, In vitro interaction assay between theYB-1truncated
variants expressed in E, coli and immobilized on the matrix and CTCF-ZF domain. The lSS·
labeled CTCF-Zn domain was generated by an in vitro translation and was incubated with
matrices containing immobilized variants ofYB·1, GST bound to Sepharose and Sepharose only,
then washed with 0,25 M RIPA buffer. Proteins retained on the matrices were analyzed by
50S-PAGE, gel dried, and exposed. M, Protein molecular weight markers in kilodaltons,
Determination of possible mechanisms by which CTCF can
antagonize YB-I regulation ofthe VNTR
To gain insight into a possible mechanism of CTCF function in
the regulation ofYB-l and VNTR domains, we aimed to deter-
mine the specific region of the YB-l protein involved in the in-
teraction with the ZF domain of CTCF. For this purpose, we
produced a series of truncated variants of the YB-l protein in E.
coli. These proteins are schematically shown in Figure 4A. Immu-
noblotting with an anti-GST antibody was used to reveal the
expressed proteins (Fig. 4B). Of all fusion proteins tested, only
GST-YB-l (5) migrated according to its predicted size. The
anomalous migration of these GST-fused YB-l constructs was
probably attributable to particular amino acid composition and
has been observed by other researchers working with GST-fused
YB-l (MacDonald et aI., 1995). Interestingly, the GST-YB-l(4)
migrated as a triplet. This YB-l truncated variant consists of the
C-terminal domain ofYB-l and contains a series offour alternat-
ing basic and acidic regions that could also be very sensitive to
spontaneous degradation (Sommerville and Ladomery, 1996).
Therefore, it is likely that the two slower migrating bands may be
the products of such degradation, Anomalous electrophoretic
migration of this mutant could be attributed to negative charges
(anomalous migration of negatively charged protein is quite
common) and has been observed in the E. coli ams protein
(Casaregola et aI., 1992) and the C-terminal domain of CTCF
(Klenova et aI., 1997).
The bacterially expressed CTCF-ZF domain was prepared
and verified with both Coomassie staining and Western assay and
coupled with the thiol-activated Sepharose as described previ-
ously (Chernukhin et aI., 2000). The interaction assay was then
performed using the truncated YB-l proteins, As shown in Fig.
4C, YB-l(l), YB-l(2), and YB-l(3) revealed clear interaction
with the immobilized ZF domain because the proteins corre-
sponding to the cognate bacterially produced GST-YB-l(l),
GST-YB-l(2), and GST-YB-l(3) were retained by CTCF-ZF.
The minimal protein sequences required for interaction in this
assay were the N-terminal sequences containing the DNA-
binding cold shock domain (CSD). When these sequences were
removed [GST- YB-l(4) and GST-YB-l(5)], no signal was de-
tected from the interaction assay, It should be noted in Figure 4C,
weak signal from a protein(s) with a molecular weight of ~60
kDa has been detected interacting with YB-l (2) and YB-l(3) and
possibly YB-l( 1) and YB-l(4). We were unable to determine the
nature of this protein, and it is unresolved whether these interac-
tions are nonspecific or attributable to homomeric formation of
YB-l (Gaudreault et aI., 2004), as might be suggested from YB-l-
(4) interactions.
The ability of GST-YB-l(l), GST-YB-l(2), and GST-YB-l(3)
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an important role in this regulation. Both YB-l and CTCF are
multifunctional and widely expressed transcription factors.
These factors are able to modulate the differential expression of
the distinct VNTR variants in a reporter gene construct, suggest-
ing that they may playa similar role in vivo.
In this study, the YB-l protein was identified as a factor inter-
acting with the Stin2 VNTR domains in the yeast "one-hybrid"
screen. The longest Stin2.12 domain contains multiple putative
YB-l binding sites (Fig. 1A, red) that are in agreement with the
consensus for the recognition motif for the family of the Y box
binding proteins (Didier et al., 1988; Wolffe et al., 1992; Wolffe,
1994). The potential importance of this transcription factor was
suggested because its DNA-binding consensus is in the same re-
gion ofeach repeat that predominantly accounts for the variation
in primary sequence between the repeats in the VNTR and addi-
tionally for the variation that accounts for the difference in size of
the repeats of either 16 or 17 bp (Fig. 1). .
All three VNTR variants (Stin2.9, Stin2.1O, and Stin2.12) and
the individual sequences representing two types ofYB-1 binding
sites within the VNTR (rp 3/4 and rp 6/7) could form specific
complexes with YB-l in EMSA (Fig. 3). rp 3/4 contains the motif
GGTG/CACC, and rp 6/7 contains the motif GATG/CATC,
which are efficiently recognized by Y-box proteins (Zasedateleva
et al., 2002). Although the lengths of the rp 3/4 and rp 6/7 oligo-
nucleotides are similar, the complexes produced by these oligo-
nucleotides in EMSA with the YB-l protein differ (Fig. 3). Differ-
ent patterns of YB-I-DNA complexes are, nevertheless, not
unusual and were observed previously for cyclin A and eye/in Bl
gene Y boxes (Jurchott et al., 2003). This phenomenon may be
explained by the differences in the primary nucleotide sequence
of the YB-l recognition sequence, which may determine the
binding characteristics ofYB-l (Spitkovsky et al., 1992). It is now
generally accepted that YB-l functions are, in part, dependent on
the DNA secondary structure (Swamynathan et al., 1998; Zase-
dateleva et al., 2002). It is therefore plausible that a particular
composition of the individual repeats in Stin2 VNTR may result
in different structural conformation of this regulatory region,
thus leading to combinatorial functional outcome. Perhaps, sig-
nificantly, the rp 6/7 element is deleted in the nine-copy VNTR;
this removes the GATGGGCT YB-l motif, which is underrepre-
sented in the VNTR domain. It is interesting that the nine-copy
variant is the most responsive to the exogenous YB-l addition in
the reporter gene analysis discussed below.
In the reporter gene assay, we have observed that differential
regulation of the VNTR function by YB-l was dependent on both
the repeat number of the VNTR and the cell type. Specifically, the
exogenously supplied YB-1 was able to progressively activate the
Stin2.9 domain, in accordance with the increasing input ofYB-l,
whereas the domains containing the 10- and 12-copy VNTR do-
main did not respond toYB-l in COS7 cells. The Stin2.9 domain
is a polymorphic variant of the Stin2 VNTR containing a deletion
of three repeats (rp 6, rp 7, and rp 8), and the Stin2.10 domain is
a polymorphic variant of the Stin2 VNTR with a deletion of two
repeats (rp 9 and rp 10) (Fig. 1B). Interestingly, the YB-l binding
site 2 (GATGGGCT), which is the underrepresented YB-l con-
sensus motif, is located inside the sequences deleted in the Stin2.9
domain. We therefore hypothesize that YB- I bound to site 2
situated within rp 6-rp 7 may have a critical role for determining
the function of the VNTR; for example, in cells such as COS7, this
site once bound by YB-l would prevent additional activation of
the 5-HITVNTR byYB-l in the Stin2.10 and Stin2.12 domains.
This might be consistent with binding ofYB-l to this site affect-
ing DNA structure in a manner distinct from the other YB-l sites
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(Zasedateleva et al., 2002); similarly, different YB-l binding sites,
once bound, can differentially alter DNA strand separation (Gau-
dreault et al., 2004). Thus, modification of DNA structure could
alter the ability ofYB-l to efficiently recognize the other consen-
sus sequences. Deletion of these sequences in the Stin2.9 domain
may therefore result in the release from inhibition by binding of
YB-l to this site in the other variants. It should, however, be
noted that in HEK 293T both Stin2.9 and Stin2.10 are activated
by YB-l, although activation of the former was much more pro-
nounced. This may be explained by the involvement of other cell
specific modulators of Stin2.10 in HEK 293T cells, by different
composition of YB-l binding sites, or combination of these pa-
rameters resulting in activation ofStin2.10 by YB-l in HEK 293T
cells. However, although YB-l may interact differentially with the
distinct consensus sequences, rp 6/7 and rp 3/4, a single base
change in the consensus sequence could not only change the
affinity and specificity ofYBI binding but also alter the comple-
ment of transcription factors capable of binding to the site. Be-
cause our data use purified transcription factors, we cannot rule
out this possibility that other factors such as that postulated
above to explain difference between reporter gene expression in
HEK 293T and COS7 cells. Indeed, search for a transcription
factor binding site using the program MatInspector (Genomatix
Suite) predicts binding of several transcription factors to rp 6/7
(GGCTGTGACCCGGGATGGGCTG). Among them are activa-
tor protein-I, Ikaros 2, TCFll/KCR-FllNrfl homodimers, and
retinoic acid receptor-related orphan receptor alphal. These
transcription factors could be expressed with a tissue-specific or
stimulus-inducible pattern, raising an additional level of com-
plexity to the regulation of the VNTR.
The interaction between YB-l and interacting partners such as
CTCF is important for regulating the expression of several genes
(Chern ukhin et al., 2000). We therefore addressed whether CTCF
would modulate either YB-l binding to the VNTR or the ability
of YB-l to regulate reporter gene expression supported by the
intron 2 VNTR. CTCF, as shown in Figure 2, by itselfhad little or
no effect on reporter gene expression directed by the VNTR,
however, it dramatically inhibited the ability ofYB-1 to regulate
VNTR supported promoter activity in the two cell lines tested.
Consistent with this finding, CTCF antagonized YB-l binding to
the VNTR in EMSA studies (Fig. 3), but no evidence was ob-
served for interaction of CTCF with the VNTR DNA sequence
in EMSA.
To interrogate the mechanism by which CTCF antagonized
YB-l regulation of VNTR function, we performed the protein-
binding studies between YB-l and CTCF outlined in Figure 4.
These experiments demonstrate that CTCF will interact with
YB-l to form a protein complex via a region encompassing the
DNA binding CSD, which constitutes the DNA-binding domain
ofYB-l. Although a more detailed mutational analysis would be
required, these data are consistent with CTCF interactions abol-
ishing the ability of YB-1 to bind to its consensus sequence, as
exemplified by our EMSA data in Figure 3. Taken together, these
observations suggest that a particular composition of the in-
dividual repeats in Stin2 VNTR and regulatory protein factors
may result in different structural and regulatory configura-
tions of this control region, which would support differential
gene expression.
Our observations further extend previous findings demon-
strating the significance ofCTCF in the regulation ofseveral neu-
ronal genes (Vostrov and Quitschke, 1997; Yang et al., 1999; Bur-
ton et al., 2002; Vostrov et al., 2002; Hikichi et al., 2003; Ulaner et
al., 2003) and the importance of YB-l in the transcription of
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neurotropic viruses (Kerr et aI., 1994; Del Valle et aI., 2000).
Thus, the mutual involvement of CTCF and YB-1 in the control
of the 5-HTT VNTR brings yet another layer of complexity in
their ability to regulate a wide variety of biological functions
ranging from cancer to neurological disorders.
Our results also further substantiate a hypothesis that the in-
dividual elements within the VNTR domain differ in their ability
to modulate transcriptional regulation in response to specific
stimuli (Fiskerstrand et aI., 1999; Lovejoy et aI., 2003). As we
demonstrate here, the VNTR elements can be activated by a tran-
scription factor(s) (e.g., YB-l) and can also be subjected to feed-
back regulation, for example, by CTCF.
We therefore conclude that the transcription of the 5-HTT
gene will be determined by the combinatorial action of multiple
positive and negative promoter domains that specify the tissue-
specific and stimulus-inducible expression of this gene (Quinn,
1996). The VNTR within intron 2 may have a direct effect on
expression of the 5-HTT gene in specific cell types or in response
to various physiological or pharmacological stimuli by synergiz-
ing with other 5-HTT promoter domains. This may correlate
with the etiology or progression of affective disorders. By them-
selves, VNTR correlation with a susceptibility to the disorder may
be low, however, because of their high frequency in the popula-
tion, they may well have a major impact when complementing
another risk factor. Demonstration of intron 2 VNTR as a differ-
ential enhancer would be consistent with our previous observa-
tions of the differential VNTR function exhibited in the initial
serotoninergic regions of the developing CNS in transgenic mod-
els carrying the VNTR supported marker of gene expression
(MacKenzie and Quinn, 1999; MacKenzie and Quinn, 2004).
Furthermore, the concept of VNTR as a differential enhancer
agrees with the hypothesis proposing that transient alterations in
serotonin homeostasis cause permanent changes to adult behav-
ior and modify the fine wiring of brain connections and that this
may, in part, happen during development (Gaspar et aI., 2003).
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